论文部分内容阅读
欧洲及澳大利亚9个中心随机双肓对64例年龄为22～35岁的低促性腺激素性不孕妇女(包括50例单纯促性腺激素分泌不足,7例垂体切除术后全垂体功能减退,3例Kallmanns’征,3例体重相关性继发闭经,1例正常促性腺激素性性腺功能低下)分组,将促性腺激素(hMG)分别与生长激素(GH)4 IU,12 IU,24 IU及安慰剂联合应用诱导排卵,以探讨GH与卵巢反应之间的剂量—效应关系。 64例随机分配至安慰剂组(16例)、4 IU GH组(16例)、12 IU GH组(17例)、24 IU GH组(15例)。结果显示:①24 IU GH组hMG使用总量(22.3±
In nine centers in Europe and Australia, 64 patients with hypogonadotrophic infertility aged 22-35 years (including 50 cases of insufficient secretion of pure gonadotropin, 7 cases of pituitary dysfunction after pituitary gastrectomy, 3 Cases of Kallmanns’ sign, 3 cases of weight-related secondary amenorrhea, 1 case of normal gonadotropin-associated hypogonadism were divided into groups and treated with 4 IU of GH, 12 IU, 24 IU of growth hormone (GH) Placebo combination induces ovulation to explore the dose-response relationship between GH and ovarian response. Sixty-four patients were randomized to placebo (16 patients), 4 IU GH patients (16 patients), 12 IU GH patients (17 patients) and 24 IU GH patients (15 patients). The results showed that: ① 24 IU GH group total hMG use (22.3 ±